Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Peptic ulcer disease is the cause for dyspepsia in about 10% of patients. 95% of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. Eradication of H pylori reduces the relapse rate of ulcers but the magnitude of this effect is uncertain. OBJECTIVES: The primary outcomes were the proportion of peptic ulcers healed initially and proportion of patients free from relapse following successful healing. Eradication therapy was compared to placebo or pharmacological therapies in H. pylori positive patients. Secondary aims included symptom relief and adverse effects. SEARCH STRATEGY: Searches were conducted on the Cochrane Central register of Controlled Trials - CENTRAL (which includes the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Trials Register) on The Cochrane Library (Issue 3 2002) MEDLINE (1966 to July 2002) and EMBASE (1980 to July 2002). Reference lists from trials selected by electronic searching were handsearched to identify further relevant trials. Published abstracts from conference proceedings from the United European Gastroenterology Week (published in Gut) and Digestive Disease Week (published in Gastroenterology) were handsearched. The search was updated in September 2003, November 2004 and November 2005. Members of the Cochrane UGPD Group, and experts in the field were contacted and asked to provide details of outstanding clinical trials and any relevant unpublished materials SELECTION CRITERIA: Randomised controlled trials of short and long-term treatment of peptic ulcer disease in H. pylori positive adults were analysed. Patients received at least one week of H pylori eradication compared with ulcer healing drug, placebo or not treatment. Trials were included if they reported assessment from 2 weeks onwards. DATA COLLECTION AND ANALYSIS: Data were collected on ulcer healing, recurrence, relief of symptoms and adverse effects. MAIN RESULTS: 63 trials were eligible. Data extraction was not possible in 7 trials, and 56 trials were included. In duodenal ulcer healing, eradication therapy was superior to ulcer healing drug (UHD) (34 trials, 3910 patients, relative risk [RR] of ulcer persisting = 0.66; 95% confidence interval [CI] = 0.58, 0.76) and no treatment (2 trials, 207 patients, RR = 0.37; 95% CI 0.26, 0.53). In gastric ulcer healing, no significant differences were detected between eradication therapy and UHD (14 trials, 1572 patients, RR = 1.25; 95% CI = 0.88, 1.76). In preventing duodenal ulcer recurrence no significant differences were detected between eradication therapy and maintenance therapy with UHD (4 trials, 319 patients, relative risk [RR] of ulcer recurring = 0.73; 95% CI = 0.42, 1.25), but eradication therapy was superior to no treatment (27 trials 2509 patients, RR = 0.20; 95% CI = 0.15, 0.26). In preventing gastric ulcer recurrence, eradication therapy was superior to no treatment (11 trials, 1104 patients, RR = 0.29; 95% CI 0.20, 0.42). AUTHORS' CONCLUSIONS: A 1 to 2 weeks course of H. pylori eradication therapy is an effective treatment for H. pylori positive peptic ulcer disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cure of duodenal ulcer associated with eradication of Helicobacter pylori
Rauws, E. A. J., & Tytgat, G. N. J. (1990) · The Lancet · doi:10.1016/0140-6736(90)91301-p · Cited by 922
Graham, D. Y., Lew, G. M., Klein, P. D., Evans, D. G., Evans, D. J., Saeed, Z. A., & Malaty, H. M. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-9-705 · Cited by 909
Hentschel, E., Brandstatter, G., Dragosics, B., Hirschl, A. M., Nemec, H., Schutze, K., Taufer, M., & Wurzer, H. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302043280503 · Cited by 708
HOSKING, S. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91460-5 · Cited by 262
Graham, D. Y., Lew, G. M., Evans, D. G., Evans, D. J., & Klein, P. D. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-4-266 · Cited by 222
Hosking, S. W., Ling, T. K., Yung, M. Y., Cheng, A., Chung, S. C., Leung, J. W., & Li, A. K. (1992) · BMJ · doi:10.1136/bmj.305.6852.502 · Cited by 117
Cited by
Hearnshaw, S. A., Logan, R. F. A., Lowe, D., Travis, S. P. L., Murphy, M. F., & Palmer, K. R. (2011) · Gut · doi:10.1136/gut.2010.228437 · Cited by 673
External Validation of a Measurement Tool to Assess Systematic Reviews (AMSTAR)
Shea, B. J., Bouter, L. M., Peterson, J., Boers, M., Andersson, N., Ortiz, Z., Ramsay, T., Bai, A., Shukla, V. K., & Grimshaw, J. M. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001350 · Cited by 569
Guidelines for the Management of Helicobacter pylori Infection in Japan: 2009 Revised Edition
Asaka, M., Kato, M., Takahashi, S., Fukuda, Y., Sugiyama, T., Ota, H., Uemura, N., Murakami, K., Satoh, K., & Sugano, K. (2010) · Helicobacter · doi:10.1111/j.1523-5378.2009.00738.x · Cited by 395
Asia–Pacific consensus guidelines on gastric cancer prevention
Fock, K. M., Talley, N., Moayyedi, P., Hunt, R., Azuma, T., Sugano, K., Xiao, S. D., Lam, S. K., Goh, K. L., Chiba, T., et al. (2008) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2008.05314.x · Cited by 354
Self-citationWatari, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5461 · Cited by 316
Metadata
- Authors
- Ford, A. C., Delaney, B., Forman, D., & Moayyedi, P.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2006-04-19
- Issue
- 2
- Pages
- CD003840-CD003840
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4245547778
- Cited by
- 123
- References
- 6
- Type
- reference entry
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. https://app.cochat.ai/papers/10.1002/14651858.cd003840.pub4
- The paper
- Ford, A. C., Delaney, B., Forman, D., & Moayyedi, P. (2006). Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd003840.pub4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.